Q2 2015 13F Holders as of 6/30/2015
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
194
-
Total 13F shares, excl. options
-
30.1M
-
Shares change
-
+1.29M
-
Total reported value, excl. options
-
$3.52B
-
Value change
-
-$43.6M
-
Put/Call ratio
-
0.9
-
Number of buys
-
121
-
Number of sells
-
-107
-
Price
-
$116.75
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2015
266 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2015.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 194 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.1M shares
of 49.6M outstanding shares and own 60.74% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP LLC (5.69M shares), FMR LLC (4.82M shares), Capital Research Global Investors (2.63M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.09M shares), VANGUARD GROUP INC (1.75M shares), Grantham, Mayo, Van Otterloo & Co. LLC (1.43M shares), FRANKLIN RESOURCES INC (1.1M shares), ORBIMED ADVISORS LLC (941K shares), JANUS CAPITAL MANAGEMENT LLC (790K shares), and Capital International Investors (650K shares).
This table shows the top 194 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.